OptimizeRx Corp. (NASDAQ:OPRX) Short Interest Down 39.0% in June

OptimizeRx Corp. (NASDAQ:OPRX) was the recipient of a significant decline in short interest in the month of June. As of June 30th, there was short interest totaling 1,129,328 shares, a decline of 39.0% from the June 15th total of 1,851,668 shares. Currently, 6.5% of the company’s shares are sold short. Based on an average daily volume of 624,522 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of OptimizeRx by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after purchasing an additional 138,224 shares during the period. Royce & Associates LP boosted its holdings in OptimizeRx by 0.7% during the 4th quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock valued at $8,362,000 after acquiring an additional 4,700 shares during the period. Kennedy Capital Management LLC increased its stake in OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after purchasing an additional 202,446 shares during the period. Rice Hall James & Associates LLC boosted its stake in shares of OptimizeRx by 1.9% in the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after purchasing an additional 11,247 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of OptimizeRx by 22.3% in the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after acquiring an additional 102,661 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Stifel Nicolaus dropped their target price on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Lake Street Capital decreased their target price on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Stephens lowered their target price on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, May 13th. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $13.43.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX traded down $0.03 during trading on Friday, reaching $6.62. 205,630 shares of the company’s stock traded hands, compared to its average volume of 451,370. The firm has a market cap of $124.19 million, a PE ratio of 18.91 and a beta of 1.08. OptimizeRx has a fifty-two week low of $4.54 and a fifty-two week high of $22.25. The company has a 50-day simple moving average of $5.46 and a 200-day simple moving average of $7.55. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. The company had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. As a group, analysts predict that OptimizeRx will post 0.51 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.